Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular gene therapy.

S Ylä-Herttuala1, J F Martin

  • 1A I Virtanen Institute and Department of Medicine, University of Kuopio, Finland. Seppo.YlaHerttuala@uku.fi

Lancet (London, England)
|February 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of a synthetic copy of the bovine chymosin gene in Aspergillus awamori from constitutive and pH-regulated promoters and secretion using two different pre-pro sequences.

Biotechnology and bioengineering·2003
Same author

The two-component PhoR-PhoP system controls both primary metabolism and secondary metabolite biosynthesis in Streptomyces lividans.

Proceedings of the National Academy of Sciences of the United States of America·2003
Same author

The cefT gene of Acremonium chrysogenum C10 encodes a putative multidrug efflux pump protein that significantly increases cephalosporin C production.

Molecular genetics and genomics : MGG·2002
Same author

Nitrate regulation of alpha-aminoadipate reductase formation and lysine inhibition of its activity in Penicillium chrysogenum and Acremonium chrysogenum.

Applied microbiology and biotechnology·2002
Same author

Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery.

European heart journal·2002
Same author

A reconsideration of the origins of the type 2 diabetes epidemic among Native Americans and the implications for intervention policy.

Medical anthropology·2002
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Vascular gene therapy shows promise for cardiovascular diseases by using gene transfer to improve blood flow and address genetic defects. Further research into vectors, delivery, and specific genes is needed to realize its full therapeutic potential.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Gene Therapy

Background:

  • Vascular gene transfer offers novel therapeutic strategies for cardiovascular diseases.
  • It enables overexpression of therapeutic proteins, correction of genetic defects, and localized gene effect testing.
  • Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene transfers have demonstrated improvements in blood flow and collateral development in ischemic conditions.

Purpose of the Study:

  • To review the potential of vascular gene transfer as a treatment for cardiovascular diseases.
  • To highlight genes and techniques showing promise in preclinical and early clinical studies.
  • To identify areas for future development in gene therapy for cardiovascular conditions.

Main Methods:

Related Experiment Videos

  • Review of preclinical studies using gene transfer in animal models of cardiovascular diseases.
  • Analysis of therapeutic genes investigated, including growth factors, enzymes, and cell cycle regulators.
  • Examination of early human trial data for vascular gene transfer.

    • Main Results:

    • Gene transfer of VEGF and FGF improved blood flow in ischemic limbs and myocardium.
    • Promising results in animal models for restenosis and vein graft thickening using various genes (e.g., nitric-oxide synthase, thymidine kinase, cyclin inhibitors) and antisense oligonucleotides.
    • Initial human experiences with VEGF gene transfer and decoy oligonucleotides have been reported.

    Conclusions:

    • Vascular gene transfer holds significant therapeutic potential for cardiovascular diseases.
    • Successful application requires advancements in gene-transfer vectors, delivery methods, and identification of effective therapeutic genes.
    • Further research and development are crucial to fully assess and implement gene therapy for cardiovascular conditions.